Bone Cancer

Dominique Heymann studied cell biology, biochemistry and immunology in INSERM (French NIH) unit 211 at the University of Nantes and received his Ph.D. in 1995. He was appointed Associate Professor in 2001 in the Department of Histology and Embryology. In 2009, he was awarded a personal Chair of Histology and Embryology.Currently he is the Quality Control Manager of the Tissue Bank and Gene and Cellular Therapy Unit at Nantes Hospital. He heads a laboratory research group (INSERM UMR 957) of 65 people at the Faculty of Medicine, where the pathogenesis of primary bone tumours, and more specifically, the role of bone microenvironment (osteoclasts, mesenchymal stem cells, OPG/RANK/RANKL, IL-6 and MCSF cytokine family) in tumour growth is studied.In 2006, Dominique Heymann won the Paul Mathieu prize from the National Academy of Medicine for his work entitled “From the osteolytic process associated to primary bone tumors to the development of bi-therapies for osteosarcoma”. He was on the national scientific advisory board of INSERM (2008-2012) and is now Co-Chairman of INSERM scientific commission n°5 (“Physiology and pathophysiology of endocrine, bone, skin and gastrointestinal tissues”). He has authored approximately 180 publications in peer- reviewed journals, more than 300 abstracts and 20 book chapters. He is also Associate Editor of Life Sciences, Academic Editor of PLoS ONE, Editor-in-Chief of the Open Bone Journal and serves on the Editorial Board of Current Medicine Chemistry, European Journal of Pharmacology, and Journal of Bone Oncology.

• Epidemiology of Bone Cancer1. Osteoarchaeology: lessons to learn from the past2. Epidemiology of primary bone tumors and economical aspects of bone metastasesModels of Bone Cancers and Technical AspectsAnimal Models3. Animal models of bone sarcomas4. In vivo models used in studies of bone metastaes5. Zebrafish models for studying bone tumorsMathematic models and machine learning6. Use of machine learning in bone cancers7. Artifical intelligence for bone cancer imagingPreparation of tissue samples: technical aspects8. Technical aspects: how do we best prepare bone samples for proper histological analysis?Bone Microenvironment and Bone CancerBone niche9. Bone niche and bone metastases 10. Bone: a fertil soil for tumor development11. Osteomimicry: old concepts and new findings Dialog between cancer cells and bone cells12. Role of mesenchymal stem cells in bone cancers, initiation, propagation and metastasis 13. Technical approaches for studying the communications between osteocytes and cancer cells14. Osteocytes and bone cancers15. Immune functions of osteoclasts: new insights for bone cancers16. Immune infiltrate in bone sarcomas17. Macrophages and pathophysiology of bone cancersMediators of cell communications18. Growth factors, cytokines and pediatric malignant primary bones tumors19. The role of NFkB in bone cancer20. TGF-beta and bone cancers: a specific focus 21. Extracellular vesicles, tumor growth and metastatic process22. Connexin43 and development of primary bone tumors : osteosarcoma and Ewing’s sarcoma23. The role of endocannabinoid system in bone cancerMetabolism24. Impact of the microenvironment acidosis on bone cancers 25. Hypoxic niche and bone cancers26. Metabolism and bone cancersBone Tumor Heterogeneity, Plasticity and BiomarkersHeterogeneity and plasticity27. EMT process in bone metastasis28. Cancer stem cells and clonal evolution in bone sarcomas29. Dormancy in cancer bone metastasisBiomarkers30. Bone Remodelling Markers and Bone Cancer 31. Epigenetic Heterogeneity in Primary Bone Cancers 32. miRNA implication in therapeutic resistance and metastatic dissemination of bone-associated tumors33. MicroRNAs and bone metastasis: how small RNAs regulate secondary tumour formation and progression in the skeleton34. Long-non coding RNA and bone sarcoma35. Liquid biopsy and circulating tumor cells in bone sarcomas: identification of new biomarkers and analysis of the tumor heterogeneity36. Disseminated tumor cells in bone marrow of cancer patients II. PRIMARY BONE TUMORSBiological aspects37. Cytogenetics of bone sarcomas 38. Genetic aspects of primary bone tumors39. Markers of bone sarcomas40. Molecular pathology of osteosarcoma41. Genomic and proteomic profiling of osteosarcoma 42. Ewing sarcoma family of tumors43. Molecular aspects of Ewing sarcomas 44. Osteoclast-rich lesions: a clinical and molecular overview45. Biology of cartilage tumor familyClinical aspects and PerspectivesImaging46. Imaging of bone sarcomas Therapeutic approaches47. Current therapeutic approaches of bone sarcomas48. Surgical approaches of bone sarcomas: Margins and clinical impact 49. Apoptosis and drug resistance in malignant bone tumors: impact on the clinical practices 50. Chondrosarcoma of Bone: Diagnosis and Therapy 51. Radiotherapy and Primary bone tumors52. New therapeutic advances of bone sarcomasIII. BONE METASTASESBiological aspects53. The histopathology of skeletal Metastases 54. Indentification of new therapeutic targets of bone cancers by proteomic strategies Clinical aspects and PerspectivesImaging55. Interventional radiologic techniques in management of bone tumors 56. Diagnosis of bone metastases in urological malignancies – an updateBone pain57. Mechanisms and management of bone cancer pain 58. Involvement of sympathic nerves in bone mestastasis59. Pain control with palliative radiotherapy in patients with bone metastases 60. Palliative care of bone metastasesTherapeutic approaches61. Radiotherapy of bone metastases62. Cellular and molecular actions of bisphosphonates: therapeutic interest in tumor-associated bone diseases63. Bone-Targeted agents and skeletal-related events in breast cancer patients with bone metastases64. Bone metastases – current status of bone-targeted treatments65. Therapies of bone metastases in castration-resistant prostate cancer66. Therapy with bone-targeting radiopharmaceuticals67. Therapeutic approaches of bone metastases associated with breast cancerMYELOMA: A BONE ASSOCIATED DISEASE68. Biological relationship between bone and myeloma cells69. Recent therapeutic approaches in myeloma

Praise for the Previous Editions:"...a comprehensive description of bone tumors from basic to clinical aspects by the most recent data available...specifically useful to medical students and scientists, health professionals, researchers and teachers working in the osteo-articular field." --Anticancer Research "Reviewing the current advances in the progression and therapeutic approaches to bone cancer is an extremely challenging task. Bone cancer is not a single disease; rather, it is a field comprising a diverse and complex range of malignancies, from primary bone tumors of stromal cell origin, to hematopoietic malignancies and secondary metastatic bone disease. Dominique Heymann has assembled an exciting, comprehensive and up-to-date series of reviews contributed by experts in the basic and clinical aspects of bone research. In the past decade, our understanding of cancers involving bone has increased tremendously, underpinned by advances in the cellular, molecular and biochemical mechanisms of bone cell interactions in health and disease, together with advances in genetics, diagnostics, imaging and therapeutic strategies. All these aspects are covered in this timely volume, which will galvanize further cooperative efforts in the coming years between basic researchers, oncologists and pathologists towards understanding the causes of different bone cancers and translating this knowledge into the clinic." --Agi E. Grigoriadis, PhD, Departments of Craniofacial Development and Orthodontics, King's College London, United Kingdom "Our understanding of bone biology and diseases has strikingly progressed in the last decade. In parallel, the processes that lead to various forms of cancer have been further unraveled and the mechanisms leading to metastatic spread further explored. In this book, Dr. Heymann has gathered some of the world experts on these subjects to explore the cutting edge where these fields merge in the context of bone cancer and metastasis, their pathophysiology, diagnosis and treatment. This encompassing book will undoubtedly meet the needs of residents and fellows as well as expert clinicians and scientists." --Roland Baron, Professor, Harvard Medical School, Boston MA, USA